VTI Appoints Dr. Juan Carlos Aragón as CEO and Executive Director
30 August 2023 - 8:47PM
Business Wire
US-based medical device firm, Visioneering Technologies,
Inc (ASX:VTI), announced the hiring of Dr. Juan Carlos Aragón
as Chief Executive Officer and Executive Director, starting October
1, 2023.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230830498188/en/
Dr. Juan Carlos Aragón, VTI CEO &
Executive Director (Photo: Business Wire)
Bringing over 30 years of experience in the vision care sector,
Dr. Aragón held high-ranking positions in global vision care
companies, managing divisions in the Americas, Asia Pacific, and
Europe. He recently served as President of CooperVision Specialty
EyeCare, overseeing products like orthokeratology, scleral lenses,
and myopia management for global markets, including being one of
the top providers in China.
On behalf of the Board of Directors, Visioneering’s Chairman,
Dr. David J. Mazzo, said:
“We are delighted and extremely fortunate to have Dr. Aragón
join the VTI team to help lead the Company through the next phase
of its growth. With his background leading global businesses,
expertise working with myopia management, and extensive experience
with the China vision care market, he is ideally suited to propel
Visioneering to future success. JC, as he is known by many, is
well-recognized as a leader in the global vision care industry. We
expect his reputation and extensive contacts will contribute
greatly to creating new opportunities for VTI.”
Dr. Aragón further affirmed the potential commercial growth
and opportunities at VTI:
“I have known VTI since its initial commercialization in 2016.
In my view, NaturalVue Multifocal is an extraordinary product for
managing both myopia and presbyopia. I have been impressed by the
success to date of the highly capable team at VTI and very much
look forward to working with them to achieve VTI’s full potential
in existing markets and new territories, especially in China. With
the interim 1-year results of the PROTECT Clinical Study to be
released in the coming months, I feel fortunate to have the
opportunity to take the helm at VTI at this pivotal time for the
Company.”
Notably, Dr. Aragón was a board member and Chair of the Global
Myopia Awareness Coalition (GMAC), emphasizing his commitment to
vision care. He also chaired the Board of Optometry Giving Sight
and served on the boards of various eye care foundations and
organizations.
For the detailed release, click here. Visioneering Technologies
Inc. (ASX:VTI) focuses on groundbreaking eye care solutions, with
its flagship product being the NaturalVue Multifocal 1 Day Contact
Lens. For more information, visit www.vtivision.com or call +1
844-884-5367, ext. 104.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230830498188/en/
Layna L. Mendlinger info@vtivision.com
Vanguard Total Stock Mar... (AMEX:VTI)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Vanguard Total Stock Mar... (AMEX:VTI)
Historical Stock Chart
Von Dez 2023 bis Dez 2024